Breast cancer is the second leading cause of cancer death in women, with over 40,000 deaths each year in the U.S. While progress has been made in the diagnosis and treatment of the over 200,000 women annually diagnosed with breast cancer, there still remains a large number of women with difficult-to-see cancers under the standard imaging modalities of mammography and ultrasound. Magnetic resonance imaging (MRI) is a significant improvement in detection of breast cancer, but its high cost, confined space, and special materials requirements have slowed the adoption of breast MRI for many cases. In particular, an efficient system for biopsy of a suspicious lesion under MRI has yet to be developed. Our robotic biopsy system is designed to surpass the current state of the art in accuracy and timeliness of MRI-guided interventions by:
This technology is secured through two patents: one for the robotics biopsy system itself and another for a breast cradle. This IP, initially developed at the University of Minnesota, was waived to the inventors and is now owned entirely by the company.
MRI Robotics is in the early stages of developing a unique system for robotic system based on a deployable base frame. This intellectual property is covered by one patent application.